Literature DB >> 15531822

Provision of on-site medical care to patients with hepatitis C in drug treatment units.

Zdravko P Vassilev, Shiela M Strauss, Janetta M Astone, Peter D Friedmann, Don C Des Jarlais.   

Abstract

Substance abusers are at high risk for hepatitis C (HCV) infection and also constitute a group that is medically underserved and hard to reach. We conducted a nationwide survey with 445 randomly selected drug treatment units in the United States to determine unit and patient characteristics associated with the provision of on-site medical services for HCV-infected drug users. Eighty-four percent of the 322 units that estimated having at least one HCV-infected patient reported that they provided patients with HCV-related medical care. Drug treatment units were more likely to provide at least some of this care on site if they were residential, part of a network, or affiliated with a hospital; had medical staff; and required that their patients undergo a medical examination before entering treatment. Some organizational factors appear to influence the provision of on-site medical services to HCV-positive patients in drug treatment units. Further research on the role of such factors could inform the development of effective models of care for patients with hepatitis C in drug treatment organizations.

Entities:  

Mesh:

Year:  2004        PMID: 15531822     DOI: 10.1353/hpu.2004.0075

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  8 in total

1.  Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.

Authors:  Hannah K Knudsen; Carrie B Oser; Amanda J Abraham; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Missed opportunities for hepatitis C testing in opioid treatment programs.

Authors:  Jemima A Frimpong
Journal:  Am J Public Health       Date:  2013-04-18       Impact factor: 9.308

3.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

4.  Hepatitis C management by addiction medicine physicians: results from a national survey.

Authors:  Alain H Litwin; Hillary V Kunins; Karina M Berg; Alex D Federman; Karyn K Heavner; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2007-03-26

5.  Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations.

Authors:  Hannah K Knudsen; Paul M Roman; Carrie B Oser
Journal:  J Addict Med       Date:  2010-06       Impact factor: 3.702

6.  Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems.

Authors:  Anita Palepu; Debbie M Cheng; Theresa Kim; David Nunes; John Vidaver; Julie Alperen; Richard Saitz; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2006-08-14

Review 7.  Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Authors:  Marija Zeremski; Jon E Zibbell; Anthony D Martinez; Steven Kritz; Bryce D Smith; Andrew H Talal
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

8.  A randomized trial of a hepatitis care coordination model in methadone maintenance treatment.

Authors:  Carmen L Masson; Kevin L Delucchi; Courtney McKnight; Jennifer Hettema; Mandana Khalili; Albert Min; Ashly E Jordan; Nicole Pepper; Jessica Hall; Nicholas S Hengl; Christopher Young; Michael S Shopshire; Jennifer K Manuel; Lara Coffin; Hali Hammer; Bradley Shapiro; Randy M Seewald; Henry C Bodenheimer; James L Sorensen; Don C Des Jarlais; David C Perlman
Journal:  Am J Public Health       Date:  2013-08-15       Impact factor: 9.308

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.